Can GLP-1s protect my heart if I can’t take estrogen?

For many women, menopause hormone therapy (MHT) can play a role in supporting heart health during midlife. But, if your doctor has told you that MHT isn’t safe for you—whether due to a history of breast cancer, blood clots, stroke, or another medical condition—you might be wondering: now what?

The good news is that you have more options than you may think. MHT isn’t the only way to support your heart in midlife. GLP-1 receptor agonists—which are currently FDA-approved for people who are obese (a BMI of 30 or greater), have type 2 diabetes, or are overweight (a BMI of at least 27) and have cardiovascular disease or other risk factors—are emerging as a promising non-hormonal option for cardiometabolic protection during menopause.

Why Heart Health Matters in Menopause

Heart disease is the leading cause of death in women, and menopause marks an important turning point in cardiovascular risk.

Estrogen does so much more than regulate your menstrual cycle during your reproductive years. It also helps protect your heart, blood vessels, metabolism, and even how your body stores fat. When estrogen declines during menopause, and replenishing those key hormone levels via MHT isn’t an option, it’s normal to feel concerned about what that means for your long-term cardiovascular health.

As estrogen levels fall, several protective processes begin to change. Blood vessels may become less flexible. Unhealthy cholesterol levels may elevate. And fat may start to appear around your abdomen—sometimes called menopause (or “meno”) belly—instead of around your hips and thighs, where it may have once been stored.

This isn’t just subcutaneous fat (the kind that sits just beneath your skin and that you can pinch). It’s visceral fat, which is stored deeper in the body and wraps around vital organs. Unlike subcutaneous fat, visceral fat is metabolically active and has been linked to several cardiometabolic changes, including:

• Insulin resistance

• Elevated inflammation

• Changes in blood sugar

• Increased cholesterol and triglycerides

Over time, these changes can raise your risk of metabolic syndrome and cardiovascular disease. That’s why midlife is often described as a critical window for prevention. Addressing these risk factors early—well before symptoms appear—can help protect your long-term heart health.

Why MHT May Not Be for Everyone—And What That Means for Heart Health

For many women, starting menopause hormone therapy (MHT) around the time of menopause may offer metabolic and cardiovascular benefits alongside menopause symptom relief. But MHT isn’t the right fit for everyone—and that’s okay.

Women with a history of hormone-sensitive cancers, blood clots, stroke, or certain cardiovascular conditions may be advised to avoid estrogen therapy altogether, or at least systemic MHT. In these cases, the natural drop in estrogen still occurs, but replacing it may carry more risk than benefit.

Local (or topical) estrogen—applied directly to the vaginal or vulvar tissues—may still be an option for managing genitourinary symptoms, as it has minimal systemic absorption compared to full-body MHT.

“Many women feel discouraged when they’re told estrogen therapy isn’t an option, because they’ve heard how protective estrogen can be for the heart. But it’s important to remember that menopause care is never a one-size-fits-all. And even when systemic estrogen isn’t appropriate, there are still effective ways to support cardiovascular health.”

Without estrogen’s steadying influence, changes in fat distribution, blood sugar regulation, and inflammation may become more pronounced. While this doesn’t mean heart disease is inevitable, it does mean that alternative prevention strategies become even more important. Lifestyle changes like diet, exercise, and even medications that target the underlying drivers of metabolic risk, like GLP-1s, can all help address these root contributors.

What Are GLP-1 Medications and How Do They Work?

GLP-1 receptor agonists were originally developed to treat type 2 diabetes. More recently, they’ve also been approved for weight management and even cardiovascular disease prevention (and management) in qualifying people.

They work by mimicking a naturally-occurring hormone in your body called glucagon-like peptide-1. This hormone helps regulate your appetite, blood sugar (glucose) levels, insulin release, and digestion. 

In practice, GLP-1 medications can:

• Reduce hunger and food intake

• Improve insulin sensitivity

• Lower blood sugar levels

• Support fat loss (especially visceral fat)

These effects are especially relevant during menopause, when weight gain and metabolic changes often become more common, despite no major changes in diet or exercise habits.

GLP-1 Medications as a Non-Hormonal Option for Cardiometabolic Protection

Let’s get one thing straight: GLP-1 receptor agonists don’t replace estrogen’s role in the body. But they may help counteract some of the downstream metabolic effects that occur when estrogen declines.

Weight loss alone can improve metabolic health, but GLP-1 receptor agonists appear to offer additional benefits beyond the number on the scale. Research suggests that these medications can help reduce abdominal obesity, improve insulin sensitivity, lower blood glucose levels, and decrease inflammatory signaling—all of which are key drivers of cardiovascular disease in postmenopausal women.

These changes may help lower overall cardiometabolic risk, especially for women who can’t take MHT.

What Does the Research Say About GLP-1s and Heart Health?

A growing body of research suggests that GLP-1 receptor agonists can improve several markers tied to cardiovascular risk, including blood pressure, cholesterol levels, blood sugar control, and inflammation.

In a recent, large clinical trial involving more than 17,000 adults living with overweight or obesity and established heart disease, participants who received a weekly semaglutide injection experienced a 20% reduction in major adverse cardiovascular events (MACE), such as heart attack and stroke, compared to those who didn’t take the medication. Following these findings, semaglutide was approved by the U.S. Food and Drug Administration (FDA) in 2024 to help lower cardiovascular risk in eligible patients.

“Medications like semaglutide, liraglutide, and tirzepatide all belong to the GLP-1 receptor agonist family. What makes them particularly exciting is that their benefits go beyond weight loss, with clinical trials showing improvements in blood sugar control, inflammation, and even reductions in cardiovascular events for certain patients.”

Although most clinical trials to date have focused on adult populations broadly (not women in menopause specifically) emerging research suggests GLP-1 therapies may be particularly helpful during estrogen-deficient states such as menopause, when the risk of metabolic syndrome rises and fat distribution often shifts toward increased abdominal adiposity.

Researchers are also beginning to explore next-generation approaches, including therapies that combine GLP-1s with estrogen. These options are still under investigation and are not yet part of routine clinical care.

Are GLP-1s Safe and Effective for Heart Health When In Menopause?

The short answer is, yes! The key is to get a GLP-1 receptor agonist prescription from a qualified doctor who can assess your health history.

No matter what stage of life you’re in, the most common side effects include:

• Nausea

• Bloating

• Constipation

• Diarrhea

Usually, these symptoms improve over time as your body adjusts to the medication.

Keep in mind, GLP-1s are only as effective as your lifestyle changes. These include eating a balanced diet, doing resistance training, and getting plenty of restorative sleep.

Talking to Your Healthcare Provider About Heart Health

If you’ve been instructed not to use estrogen-based MHT, consider asking a menopause-informed clinician about other ways you can support your cardiovascular health during menopause. From there, they can develop a personalized risk assessment to determine whether non-hormonal options, such as GLP-1 medications, might be appropriate for you.

You might ask:

• What is my current cardiometabolic risk?

• Are there lifestyle or medication-based strategies that could help lower it?

• Do I qualify for a GLP-1 medication and would it be appropriate for long-term care?

• How would this fit into my overall menopause care plan?

The bottom line is this: estrogen plays an important role in heart health, but it’s not the only tool available. With the right support and individualized care plan, there are evidence-based ways to protect your cardiovascular health during menopause, even when MHT isn’t an option.

Frequently Asked Questions Why does heart disease risk increase during menopause?

During menopause, the decline in estrogen levels removes a key layer of cardiovascular protection. Estrogen helps maintain flexible blood vessels and regulates how the body stores fat. As levels drop, many women experience a shift toward visceral fat storage (often called "meno-belly"), which wraps around vital organs. This type of fat is metabolically active and can lead to insulin resistance, elevated inflammation, and higher cholesterol levels, all of which increase the risk of heart disease.

Can GLP-1 medications help protect heart health if I cannot take hormone therapy?

Yes. While GLP-1 receptor agonists (like semaglutide) do not replace estrogen, they can help counteract the downstream metabolic effects that occur when estrogen declines. These non-hormonal medications help reduce abdominal obesity, improve insulin sensitivity, and lower inflammatory signaling. Recent clinical research involving over 17,000 adults showed that these medications can lead to a 20% reduction in major adverse cardiovascular events, such as heart attacks and strokes.

Who is eligible for GLP-1 medications during menopause?

GLP-1 medications are currently FDA-approved for individuals who meet specific health criteria. This includes people with a BMI of 30 or greater (obesity), or those with a BMI of at least 27 (overweight) who also have type 2 diabetes, cardiovascular disease, or other high-risk factors. If you have been advised against systemic Menopause Hormone Therapy (MHT) due to a history of blood clots, stroke, or hormone-sensitive cancers, a GLP-1 may be a viable alternative for cardiometabolic protection.

What are the side effects of using GLP-1s for cardiometabolic health?

The most common side effects associated with GLP-1 receptor agonists include gastrointestinal symptoms such as nausea, bloating, constipation, and diarrhea. For most patients, these symptoms are temporary and improve as the body adjusts to the medication. To maximize effectiveness and heart health benefits, these medications should be paired with lifestyle changes, including a balanced diet, resistance training, and restorative sleep.